ArticleJournal of gastrointestinal oncology2025
Survival outcomes of patients after liver transplantation for patients with hepatocellular carcinoma exceeding the Hangzhou criteria.
Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patient selection is one of the key factors influencing prognosis after liver transplantation (LT), and a number of selection criteria have been proposed and broadly applied. The benefit of LT is debatable when patients exceed these criteria in light of liver worldwide donor shortage. This study aims to identify key prognostic indicators predicting patients undergoing LT beyond Hanzhou criteria, to guide LT candidate selection. Methods: The clinical data and pathological findings of patients who underwent LT in the Liver Transplantation Center of General Hospital of Southern Theater Command from September 2003 to August 2017 were collected for retrospective analysis, only patients exceeding the Hangzhou criteria were enrolled. Patients were followed up until December 1, 2023; disease-free survival (DFS) and overall survival (OS) was analyzed; and predictive models of DFS and OS were constructed and validated. Results: A total of 161 patients were included in the analysis. A tumor diameter ≥6 cm [hazard ratio (HR) =2.01; P=0.01], alpha fetoprotein (AFP) levels >1,000 ng/mL (HR =2.68; P<0.001), lack of metformin administration (HR =2.98; P=0.008), operative blood loss >2,000 mL (HR =1.75; P=0.01), and female donor gender (HR =3.71; P=0.004) were independent risk factors for lower DFS, while a tumor diameter ≥6 cm (HR =2.05; P=0.001), AFP level >1,000 ng/mL (HR =1.54; P=0.04), and female donor gender (HR =4.45; P<0.001) were independent predictors of worse OS. Patients with a preoperative AFP level ≤1,000 ng/mL or a history of metformin administration had a significantly better prognosis after LT. Conclusions: For patients exceeding the Hangzhou criteria, those with an AFP level ≤1,000 ng/mL can still achieve acceptable long-term prognosis after LT. Administration of metformin has a strong positive association with longer recurrence-free survival. The patient criteria for selection for LT can be tentatively expanded.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.